{"name": "Nuclea Biotechnologies",
 "permalink": "nuclea-biotechnologies",
 "crunchbase_url": "http://www.crunchbase.com/company/nuclea-biotechnologies",
 "homepage_url": "http://www.nucleabio.com/",
 "blog_url": "http://nucleabiomarkers.blogspot.in/",
 "blog_feed_url": "",
 "twitter_username": "nucleabio",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2005,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@nucleabio.com",
 "phone_number": "413-749-4705",
 "description": "",
 "created_at": "Tue Jan 25 04:16:43 UTC 2011",
 "updated_at": "Mon Mar 25 07:50:08 UTC 2013",
 "overview": "\u003Cp\u003ENuclea Biotechnologies, LLC is headquartered in Pittsfield, Massachusetts with additional operations in Worcester, Massachusetts. Nuclea has three lines of business, each of which is operated by a separate wholly-owned subsidiary: Nuclea Diagnostic Laboratories (\u00e2\u20ac\u0153NDL\u00e2\u20ac\u009d) which has developed and is commercializing eleven unique diagnostic tests for colon, breast, leukemia, lung and prostate cancer; Nuclea Biomarkers (\u00e2\u20ac\u0153NBM\u00e2\u20ac\u009d) which performs research leading to novel molecular oncology therapeutics and diagnostics for the pharmaceutical and biotechnology industries and performs services by analyzing and testing the efficacy and validating other indications of existing therapeutics utilizing a highly characterized and consented patient database; and Nuclea Biotherapeutics (\u00e2\u20ac\u0153NBT\u00e2\u20ac\u009d) which has developed several therapeutics now in animal trials.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       45],
      "assets/images/resized/0011/8829/118829v1-max-150x150.png"],
     [[249,
       75],
      "assets/images/resized/0011/8829/118829v1-max-250x250.png"],
     [[249,
       75],
      "assets/images/resized/0011/8829/118829v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$17.3M",
 "funding_rounds":
  [{"round_code": "b",
    "source_url": "http://www.masshightech.com/stories/2011/08/15/daily52-Nuclea-Biotechnologies-lands-3M-funding.html",
    "source_description": "Nuclea Biotechnologies lands $3M funding",
    "raised_amount": 3000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 8,
    "funded_day": 19,
    "investments":
     []},
   {"round_code": "b",
    "source_url": "http://www.masshightech.com/stories/2011/10/10/daily19-Nuclea-nudges-latest-funding-round-to-64M.html",
    "source_description": "Nuclea nudges latest funding round to $6.4M",
    "raised_amount": 3400000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 10,
    "funded_day": 11,
    "investments":
     []},
   {"round_code": "b",
    "source_url": "http://www.masshightech.com/stories/2012/01/30/daily87-Nuclea-adds-34M-to-funding-round.html",
    "source_description": "Nuclea adds $3.4M to funding round",
    "raised_amount": 3400000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 2,
    "funded_day": 2,
    "investments":
     []},
   {"round_code": "unattributed",
    "source_url": "http://www.masshightech.com/stories/2012/04/09/daily43-Nuclea-receives-19M-fundraise.html",
    "source_description": "Nuclea receives $1.9M fundraise",
    "raised_amount": 1900000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 4,
    "funded_day": 12,
    "investments":
     []},
   {"round_code": "unattributed",
    "source_url": "http://www.masshightech.com/stories/2012/04/30/daily42-Pittsfield-biomarker-discovery-business-raises-555K.html",
    "source_description": "Pittsfield biomarker discovery business raises $555K",
    "raised_amount": 555000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 5,
    "funded_day": 3,
    "investments":
     []},
   {"round_code": "c",
    "source_url": "http://www.masshightech.com/stories/2012/07/30/daily39-Nuclea-raises-5M-in-first-Series-C-round.html",
    "source_description": "Nuclea raises $5M in first Series C round",
    "raised_amount": 5000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 8,
    "funded_day": 2,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "105 South Street",
    "address2": "",
    "zip_code": "01201 ",
    "city": "Pittsfield",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Nuclea, Boston Medical Center partner in $1.4M R\u0026D deal",
    "stoned_year": 2011,
    "stoned_month": 1,
    "stoned_day": 24,
    "source_url": "http://www.masshightech.com/stories/2011/01/24/daily9-Nuclea-Boston-Medical-Center-partner-in-14M-RD-deal.html",
    "source_text": "",
    "source_description": "Nuclea, Boston Medical Center partner in $1.4M R\u0026D deal",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Nuclea Biotechnologies",
      "permalink": "nuclea-biotechnologies"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}